Q3 2024 Earnings

Revenue

$8M+41.0% YoY

Gross Profit

$5M59.7% margin

Operating Income

-$5M-63.7% margin

Net Income

-$5M-61.2% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+3.4%

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$2M

Total Assets

$40M

Total Liabilities

$11M

Stockholders' Equity

$29M

Cash & Equivalents

$22M

Metric	Current	Year Ago	Change
Revenue	$8M	$6M	+41.0%
Gross Profit	$5M	$3M	+48.1%
Operating Income	-$5M	-$5M	-5.6%
Net Income	-$5M	-$5M	-3.4%

Biologics And Drug Delivery

$4M54%

Biologics And Drug Delivery - Disposable Products

$2M25%

Capital Equipment And Software

$831,00010%

Capital Equipment And Software - Systems and Software Products

$552,0007%

Capital Equipment And Software - Services

$279,0003%